Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TROMETHAMINE vs MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Tromethamine is a proton acceptor that buffers hydrogen ions, correcting metabolic acidosis by increasing bicarbonate and base excess. It acts as a weak base with high buffering capacity.
Magnesium hydroxide is an antacid that neutralizes gastric acid, increasing gastric p H. Omeprazole is a proton pump inhibitor (PPI) that irreversibly inhibits the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, blocking the final step of acid secretion. Sodium bicarbonate is a systemic antacid that neutralizes gastric acid and also provides alkalinization of urine.
Metabolic acidosis associated with cardiac arrest,Correction of metabolic acidosis in acute respiratory acidosis,Metabolic acidosis in renal failure,Metabolic acidosis in diabetes mellitus
Treatment of frequent heartburn (FDA-approved for over-the-counter use),Gastroesophageal reflux disease (GERD),Erosive esophagitis,Duodenal ulcer,Gastric ulcer,Zollinger-Ellison syndrome,Helicobacter pylori eradication (as part of combination therapy)
Intravenous: 1 M solution (3.6 g/30 m L) administered via central line; usual adult dose 300-500 mg/kg (0.27-0.45 g/kg) given over 1-2 hours; may be repeated based on blood gas monitoring.
One tablet (containing 400 mg magnesium hydroxide, 20 mg omeprazole, 1000 mg sodium bicarbonate) orally once daily, taken at least 1 hour before a meal.
Terminal elimination half-life: 2–3 hours in adults with normal renal function. May be prolonged in renal impairment.
Magnesium hydroxide: not applicable (local action); omeprazole: 0.5-1 hour (terminal); sodium bicarbonate: not applicable (buffering agent). Omeprazole's half-life is short but pharmacodynamic effect (acid suppression) lasts ~24 hours due to covalent binding to proton pumps.
Tromethamine is not metabolized; it is primarily excreted unchanged by the kidneys.
Omeprazole is extensively metabolized in the liver via CYP2C19 and CYP3A4; its metabolites are inactive. Magnesium hydroxide and sodium bicarbonate are not metabolized; they act locally and are partially absorbed. Sodium bicarbonate is converted to carbon dioxide and water via carbonic anhydrase.
Renal excretion of unchanged drug: >95%. Negligible biliary or fecal elimination.
Magnesium hydroxide: primarily fecal (unabsorbed magnesium), renal (absorbed magnesium); omeprazole: renal (~77% as metabolites) and fecal (~23%); sodium bicarbonate: renal (as bicarbonate or CO2).
<10% bound to plasma proteins (albumin).
Magnesium hydroxide: negligible; omeprazole: 95% (albumin and alpha1-acid glycoprotein); sodium bicarbonate: negligible.
0.3–0.4 L/kg; primarily distributes in extracellular fluid.
Magnesium hydroxide: not applicable (local); omeprazole: 0.3-0.5 L/kg (extensive tissue distribution); sodium bicarbonate: 0.5-1 L/kg (total body water).
Not available (administered intravenously only; oral bioavailability is negligible due to lack of absorption).
Magnesium hydroxide: not absorbed orally; omeprazole: 30-40% (oral, delayed-release formulation); sodium bicarbonate: 100% (oral, completely absorbed).
Contraindicated in anuria or severe renal impairment (GFR < 30 m L/min). Use with caution in renal insufficiency; monitor acid-base balance. No specific dose adjustment guidelines; avoid in renal failure.
Contraindicated in severe renal impairment (e GFR <30 m L/min/1.73m²) due to risk of magnesium accumulation and sodium overload. For e GFR 30-59 m L/min/1.73m², reduce dose to one tablet every other day and monitor serum magnesium and sodium.
No specific Child-Pugh based dose adjustments; use with caution in hepatic impairment as metabolism is minimal (primarily renal excretion). Monitor electrolytes and p H.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce omeprazole dose to 10 mg (not available in this combination) or consider alternative; use with caution. Child-Pugh C: Contraindicated due to omeprazole accumulation.
Intravenous: 1 M solution; dose based on calculated base deficit: m L of 0.3 M THAM = body weight (kg) × base deficit (m Eq/L) × 1.1. Administer over 1-2 hours via central line. Maximum infusion rate: 5 m L/kg/hour.
Not recommended for use in pediatric patients (safety and efficacy not established).
No specific dose adjustment; monitor renal function and avoid in geriatric patients with renal impairment due to decreased creatinine clearance. Use lower end of dosing range and monitor acid-base status frequently.
Use with caution due to increased risk of electrolyte imbalance (hypermagnesemia, metabolic alkalosis) and renal impairment. Consider reducing dose to one tablet every other day. Monitor renal function and serum electrolytes.
There is no FDA black box warning for tromethamine.
None
Monitor blood p H, p CO2, and electrolytes (especially potassium) during infusion,Use with caution in patients with renal impairment due to risk of accumulation,May cause respiratory depression, especially in patients with impaired renal function,Avoid extravasation due to tissue necrosis,Not recommended for neonatal use due to risk of hyperosmolality
Long-term use (≥1 year) may increase risk of osteoporosis-related fractures; hypomagnesemia with prolonged PPI use; cyanocobalamin (vitamin B12) deficiency with long-term acid suppression; magnesium hydroxide may cause diarrhea; sodium bicarbonate may cause metabolic alkalosis, fluid retention, and worsen hypertension or heart failure; acute interstitial nephritis reported with PPIs; monitor renal function; interaction with clopidogrel (omeprazole reduces clopidogrel's active metabolite); increased risk of Clostridium difficile infection; avoid concurrent use of atazanavir or nelfinavir.
Anuria or uremia,Chronic respiratory acidosis,Hypoglycemia,Hyperkalemia,Hypocalcemia,Known hypersensitivity to tromethamine
Hypersensitivity to any component; Concurrent use of rilpivirine-containing products; Severe renal impairment (Cr Cl <30 m L/min) due to risk of magnesium toxicity; Sodium-restricted diet (due to sodium content); Patients with metabolic alkalosis; Children under 12 years for over-the-counter use (varies by product).
No known food interactions. However, electrolyte imbalances (e.g., hypokalemia) may be affected by dietary potassium intake; maintain a balanced diet per clinician advice.
Take on empty stomach; food reduces omeprazole absorption. Avoid high-fat meals. No known specific food interactions with antacid components.
Tromethamine is a parenteral alkalinizing agent used in metabolic acidosis. Animal reproduction studies have not been conducted. It is not known whether tromethamine can cause fetal harm when administered to a pregnant woman. Use during pregnancy only if clearly needed. Risk cannot be ruled out.
First trimester: No evidence of teratogenicity from omeprazole or magnesium hydroxide; sodium bicarbonate may cause metabolic alkalosis. Second and third trimesters: Omeprazole is considered low risk; magnesium hydroxide can cause hypotonia and respiratory depression in neonates with prolonged use; sodium bicarbonate may lead to fluid overload or alkalosis.
It is not known whether tromethamine is excreted in human milk. The M/P ratio is undetermined. Caution should be exercised when administered to a nursing woman.
Omeprazole is excreted in breast milk in low amounts (M/P ratio ~0.5); magnesium hydroxide and sodium bicarbonate are poorly absorbed; considered compatible with breastfeeding, but monitor infant for diarrhea or electrolyte imbalance.
No specific dosing adjustments are recommended for pregnancy. However, pharmacokinetic changes in pregnancy (increased plasma volume, altered renal function) may necessitate careful monitoring and titration based on clinical and laboratory response.
No dose adjustment typically required; monitor for magnesium toxicity in renal impairment; consider reduced omeprazole dose if CYP2C19 polymorphisms present; sodium bicarbonate dose should be adjusted to avoid metabolic alkalosis.
Tromethamine (THAM) is an amino alcohol that acts as a proton acceptor, used to correct metabolic acidosis when sodium bicarbonate is contraindicated (e.g., hypernatremia, hypercapnia). It is preferred in patients with lactic acidosis or respiratory acidosis because it does not generate CO2. Monitor serum potassium closely as it can cause hypokalemia. Extravasation causes tissue necrosis; administer via central line if possible. Correct dosing is based on base deficit: m L of 0.3 M THAM = base deficit (m Eq/L) × weight (kg) × 1.1.
This combination uses sodium bicarbonate to rapidly raise gastric p H, enabling omeprazole absorption (enteric-coated omeprazole may be prematurely released; use non-enteric formulations). Magnesium hydroxide provides additional acid neutralization and a laxative effect. Avoid in patients with renal impairment (risk of magnesium toxicity, sodium overload). Administer on an empty stomach at least 1 hour before meals. Do not split or crush tablets.
This medication is used to treat acidosis (too much acid in the blood).,It is given intravenously (IV) by your healthcare provider.,Report any signs of IV site reaction: pain, redness, swelling, or blistering.,You may need frequent blood tests to monitor your acid-base balance and potassium levels.,Tell your doctor if you have kidney disease or low blood potassium before treatment.
Take this medication on an empty stomach at least 1 hour before a meal.,Swallow the tablet whole; do not crush or chew it.,Do not take with other antacids or calcium supplements.,Notify your doctor if you have kidney disease or are on a low-sodium diet.,Common side effects include diarrhea or stomach pain; report severe or persistent symptoms.,Avoid alcohol and NSAIDs as they can worsen stomach irritation.
"Methotrimeprazine may reduce the gastrointestinal absorption of tromethamine, an alkalinizing agent, leading to decreased systemic exposure and potentially diminished therapeutic efficacy. This interaction is hypothesized to occur via altered gastric pH or motility, though direct evidence is limited. Patients may experience reduced effectiveness of tromethamine in managing acid-base disorders."
"Tromethamine, an alkalinizing agent used to correct metabolic acidosis, can increase gastric pH, which may reduce the absorption of weakly acidic drugs like estrone sulfate. This altered gastrointestinal environment can decrease estrone sulfate bioavailability, potentially compromising its systemic effects for hormone replacement therapy. Clinically, this may lead to reduced efficacy of estrone sulfate, requiring dose adjustments or alternative administration routes."
"Tromethamine, an alkalinizing agent, can increase urinary pH, which enhances the renal excretion of sotalol, a class III antiarrhythmic that is primarily eliminated unchanged by the kidneys. This interaction may lead to reduced serum sotalol concentrations, potentially decreasing its therapeutic efficacy and increasing the risk of arrhythmia recurrence, particularly in patients with renal impairment or those requiring precise antiarrhythmic control."
"Niclosamide may inhibit the cytochrome P450 enzyme CYP2C19, which is the primary hepatic enzyme responsible for the metabolism of omeprazole. This inhibition can lead to decreased clearance and elevated plasma concentrations of omeprazole, potentially increasing its therapeutic and adverse effects. Clinically, this could result in enhanced acid suppression and an increased risk of omeprazole-related side effects such as headache, diarrhea, or vitamin B12 deficiency with prolonged use."
"Cyclosporine, a potent immunosuppressant and P-glycoprotein inhibitor, can significantly increase the systemic exposure of omeprazole by inhibiting its efflux transport and potentially its metabolism via CYP3A4 and CYP2C19. This interaction may lead to elevated omeprazole serum concentrations, increasing the risk of adverse effects such as headache, diarrhea, and vitamin B12 deficiency with long-term use. Clinicians should be vigilant for signs of omeprazole toxicity when coadministered with cyclosporine."
"Omeprazole, a proton pump inhibitor (PPI), is primarily metabolized by cytochrome P450 (CYP)2C19 and, to a lesser extent, CYP3A4. Stiripentol, an antiepileptic drug, is a potent inhibitor of CYP2C19 and CYP3A4. Coadministration may lead to a significant increase in omeprazole exposure (AUC up to 5-fold), potentially increasing the risk of adverse effects such as hypomagnesemia, Clostridioides difficile infection, or bone fracture. Conversely, stiripentol levels are not expected to be significantly affected, as omeprazole does not inhibit its metabolism."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TROMETHAMINE vs MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE, answered by our medical review team.
TROMETHAMINE is a Alkalinizing Agent (Buffer) that works by Tromethamine is a proton acceptor that buffers hydrogen ions, correcting metabolic acidosis by increasing bicarbonate and base excess. It acts as a weak base with high buffering capacity.. MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE is a Alkalinizing Agent that works by Magnesium hydroxide is an antacid that neutralizes gastric acid, increasing gastric p H. Omeprazole is a proton pump inhibitor (PPI) that irreversibly inhibits the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, blocking the final step of acid secretion. Sodium bicarbonate is a systemic antacid that neutralizes gastric acid and also provides alkalinization of urine.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TROMETHAMINE and MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TROMETHAMINE is: Intravenous: 1 M solution (3.6 g/30 m L) administered via central line; usual adult dose 300-500 mg/kg (0.27-0.45 g/kg) given over 1-2 hours; may be repeated based on blood gas monitoring.. The standard adult dose of MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE is: One tablet (containing 400 mg magnesium hydroxide, 20 mg omeprazole, 1000 mg sodium bicarbonate) orally once daily, taken at least 1 hour before a meal.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TROMETHAMINE and MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TROMETHAMINE is classified as Category C. Tromethamine is a parenteral alkalinizing agent used in metabolic acidosis. Animal reproduction studies have not been conducted. It is not known whether tromethamine can cause feta. MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE is classified as Category A/B. First trimester: No evidence of teratogenicity from omeprazole or magnesium hydroxide; sodium bicarbonate may cause metabolic alkalosis. Second and third trimesters: Omeprazole is . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.